

# Cell and Gene Therapy Manufacturing Industry is projected to surpass a valuation of US\$ 240 Billion by 2033 | FMI

*USA dominated cell & gene therapy market revenues, driven by active trials & extensive R&D, making North America a leader in trials.*



NEWARK, DELAWARE, UNITED STATES OF AMERICA, December 7, 2023 /EINPresswire.com/ -- The global [cell and gene therapy manufacturing industry](#) is anticipated to create phenomenal growth opportunities over the forecast period by registering a CAGR of 29% from 2023 to 2033. The global market reached a valuation of around US\$ 19.3 Billion in 2023 and is expected to surpass a valuation of around US\$ 240 Billion by 2033. As per the Cell and Gene Therapy Manufacturing Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 22% CAGR.

Market revenue through cell therapy manufacturing market size is expected to be the highest revenue-generating segment, accounting for an expected CAGR of 31.8% from 2023 to 2033. The augmenting frequency of cancer and other target diseases, combined with increasing research and development spending in pharmaceutical companies, are driving market expansion.

Request A Sample Copy of This Report:

<https://www.futuremarketinsights.com/reports/sample/rep-gb-16515>

Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatments that are excessively utilized to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth. In addition to that, it has been estimated that more than 50 million people will be diagnosed with cancer within the next five years.

Report Highlights:

Breast cancer has significantly suppressed lung cancer, by being one of the most commonly diagnosed cancers worldwide. For the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.

Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.

GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.

#### Recent Developments:

There are approximately 1,200 cell and gene therapies in clinical trials worldwide. In the USA alone, there are around 700 investigational cell and gene therapies in clinical trials.

Various manufacturing facilities are unable to keep up with global requirements. Hundreds of more facilities are expected to be required to manufacture the therapies currently in clinical development. Viral capacity is one of the areas that has to be accelerated.

Viral vectors in gene therapy, often manufactured using expensive adherent processes, incur high production costs, ranging from US\$ 500,000 to US\$ 1 million per therapy, excluding additional expenses. A vial of 20 million cells for viral vectors can cost US\$ 20,000 to US\$ 30,000 to generate.

#### Competitive Landscape:

Rising investor interest in advanced therapies and strategic initiatives like mergers and acquisitions drive market revenue growth in the forecast period. Key firms enhance market presence through partnerships and licensing.

Gain Access to Detailed Market Insights: Purchase to Uncover Segment-specific Information, Identify Key Trends, Drivers, and Challenges:

<https://www.futuremarketinsights.com/checkout/16515>

#### Key Companies Profiled:

Thermo Fisher Scientific  
Merck KGaA  
Lonza  
Catalent Inc.  
Takara Bio Inc.  
F. Hoffmann-La Roche Ltd  
Wuxi Advanced Therapies  
Samsung Biologics  
Boehringer Ingelheim

Novartis AG  
Hitachi Chemical Co., Ltd.  
Cellular Therapeutics  
Miltenyi Biotec  
Bluebird Bio Inc.

#### More Insights into the Cell and Gene Therapy Manufacturing Market:

North America is set to dominate the global cell and gene therapy manufacturing market, with the U.S.A. contributing significantly in 2022 due to a multitude of active clinical trials and extensive engagement in gene and cell therapy research. The region, boasting over 400 businesses involved in gene therapy development, leads in gene therapy clinical trials.

The UK market is poised for positive growth, contributing to the European region's projected valuation of US\$ 6.5 Billion by 2033, with a CAGR of 23.9%, presenting a substantial absolute dollar opportunity of US\$ 5.7 Billion.

Japan anticipates significant growth in the global market, with a projected CAGR of 32.5% from 2023 to 2033, reaching a valuation of US\$ 12.6 Billion and presenting an absolute dollar opportunity of US\$ 11.9 Billion.

#### Segments Covered in Cell and Gene Therapy Manufacturing Market Analysis:

##### By Therapy Type:

Cell Therapy Manufacturing  
Stem Cell Therapy  
Non-Stem Cell Therapy  
Gene Therapy Manufacturing

##### By Scale:

Pre-commercial/ R&D Manufacturing  
Commercial Scale Manufacturing

##### By Mode:

Contract Manufacturing  
In-house Manufacturing

##### By Workflow:

Cell Processing

Cell Banking  
Process Development  
Fill & Finish Operations  
Analytical And Quality Testing  
Raw Material Testing  
Vector Production  
Other Workflows

By Region:

North America  
Latin America  
Europe  
Asia Pacific  
Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Explore FMI's related ongoing Coverage on Healthcare Market Insights Domain

[Cell Therapy Manufacturing Market Share](#): is to expand at a CAGR of 14.2% from 2023 to 2033. The market is anticipated to reach a valuation of ~US\$ 15,634.67 million by the end of 2033.

[Single Dose Radiotherapy Services Market Share](#): The global market is expected to attain a valuation of US\$ 7.88 billion in 2023 and is projected to reach US\$ 16 billion by 2033.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam  
Future Market Insights, Inc.  
+ +91 90966 84197

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/673522796>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.